15.26 USD
-0.19 (-1.23%)
15.34 USD
+0.08 (+0.52%)
Overall SGRY gets a fundamental rating of 3 out of 10. We evaluated SGRY against 101 industry peers in the Health Care Providers & Services industry. While SGRY is still in line with the averages on profitability rating, there are concerns on its financial health. SGRY has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
SGRY had positive earnings in the past year.
In the past year SGRY had a positive cash flow from operations.
SGRY had negative earnings in each of the past 5 years.
In the past 5 years SGRY always reported a positive cash flow from operatings.
1.2 Ratios
With a Return On Assets value of -2.16%, SGRY perfoms like the industry average, outperforming 41.58% of the companies in the same industry.
SGRY has a Return On Equity of -9.94%. This is comparable to the rest of the industry: SGRY outperforms 43.56% of its industry peers.
The Return On Invested Capital of SGRY (5.57%) is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for SGRY is below the industry average of 9.58%.
The 3 year average ROIC (5.03%) for SGRY is below the current ROIC(5.57%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.16% | ||
| ROE | -9.94% | ||
| ROIC | 5.57% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
1.3 Margins
SGRY has a Operating Margin of 15.78%. This is amongst the best in the industry. SGRY outperforms 92.08% of its industry peers.
In the last couple of years the Operating Margin of SGRY has remained more or less at the same level.
The Gross Margin of SGRY (26.57%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of SGRY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.78% | ||
| PM (TTM) | N/A | ||
| GM | 26.57% |
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SGRY is destroying value.
SGRY has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SGRY has been increased compared to 5 years ago.
The debt/assets ratio for SGRY is higher compared to a year ago.
2.2 Solvency
SGRY has an Altman-Z score of 0.76. This is a bad value and indicates that SGRY is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.76, SGRY is not doing good in the industry: 76.24% of the companies in the same industry are doing better.
The Debt to FCF ratio of SGRY is 18.37, which is on the high side as it means it would take SGRY, 18.37 years of fcf income to pay off all of its debts.
SGRY has a Debt to FCF ratio (18.37) which is comparable to the rest of the industry.
SGRY has a Debt/Equity ratio of 2.00. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.00, SGRY is not doing good in the industry: 72.28% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2 | ||
| Debt/FCF | 18.37 | ||
| Altman-Z | 0.76 |
ROIC/WACC0.62
WACC9.02%
2.3 Liquidity
A Current Ratio of 1.88 indicates that SGRY should not have too much problems paying its short term obligations.
SGRY's Current ratio of 1.88 is fine compared to the rest of the industry. SGRY outperforms 77.23% of its industry peers.
SGRY has a Quick Ratio of 1.72. This is a normal value and indicates that SGRY is financially healthy and should not expect problems in meeting its short term obligations.
SGRY has a better Quick ratio (1.72) than 72.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.72 |
3. Growth
3.1 Past
The earnings per share for SGRY have decreased strongly by -17.02% in the last year.
The Revenue has grown by 10.14% in the past year. This is quite good.
SGRY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.20% yearly.
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
Revenue 1Y (TTM)10.14%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%
3.2 Future
SGRY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.89% yearly.
Based on estimates for the next years, SGRY will show a small growth in Revenue. The Revenue will grow by 7.88% on average per year.
EPS Next Y-29.92%
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
EPS Next 5Y12.89%
Revenue Next Year6.88%
Revenue Next 2Y7.52%
Revenue Next 3Y7.62%
Revenue Next 5Y7.88%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 19.56 indicates a rather expensive valuation of SGRY.
SGRY's Price/Earnings ratio is a bit cheaper when compared to the industry. SGRY is cheaper than 71.29% of the companies in the same industry.
SGRY's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.60.
Based on the Price/Forward Earnings ratio of 20.35, the valuation of SGRY can be described as rather expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as SGRY.
When comparing the Price/Forward Earnings ratio of SGRY to the average of the S&P500 Index (23.23), we can say SGRY is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.56 | ||
| Fwd PE | 20.35 |
4.2 Price Multiples
78.22% of the companies in the same industry are more expensive than SGRY, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SGRY indicates a rather cheap valuation: SGRY is cheaper than 85.15% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.17 | ||
| EV/EBITDA | 8.31 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
5. Dividend
5.1 Amount
SGRY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
15.26
-0.19 (-1.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners80.81%
Inst Owner Change5.61%
Ins Owners1.11%
Ins Owner Change-0.17%
Market Cap1.97B
Revenue(TTM)3.29B
Net Income(TTM)-171.90M
Analysts81.11
Price Target26.52 (73.79%)
Short Float %18.68%
Short Ratio7.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.56%
Min EPS beat(2)-23.03%
Max EPS beat(2)24.15%
EPS beat(4)2
Avg EPS beat(4)-2.06%
Min EPS beat(4)-24.34%
Max EPS beat(4)24.15%
EPS beat(8)5
Avg EPS beat(8)2.45%
EPS beat(12)9
Avg EPS beat(12)185.54%
EPS beat(16)10
Avg EPS beat(16)107.47%
Revenue beat(2)0
Avg Revenue beat(2)-1.38%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)-0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.63%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)2.34%
Revenue beat(8)3
Avg Revenue beat(8)-0.61%
Revenue beat(12)4
Avg Revenue beat(12)-0.71%
Revenue beat(16)5
Avg Revenue beat(16)-1.03%
PT rev (1m)-8.13%
PT rev (3m)-16.67%
EPS NQ rev (1m)-1.75%
EPS NQ rev (3m)-34.77%
EPS NY rev (1m)-24.86%
EPS NY rev (3m)-25.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.75%
Revenue NY rev (1m)-1.84%
Revenue NY rev (3m)-1.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.56 | ||
| Fwd PE | 20.35 | ||
| P/S | 0.6 | ||
| P/FCF | 10.17 | ||
| P/OCF | 7 | ||
| P/B | 1.14 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.31 |
EPS(TTM)0.78
EY5.11%
EPS(NY)0.75
Fwd EY4.91%
FCF(TTM)1.5
FCFY9.83%
OCF(TTM)2.18
OCFY14.28%
SpS25.42
BVpS13.37
TBVpS-26.33
PEG (NY)N/A
PEG (5Y)N/A
Graham Number15.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.16% | ||
| ROE | -9.94% | ||
| ROCE | 7.05% | ||
| ROIC | 5.57% | ||
| ROICexc | 5.57% | ||
| ROICexgc | 18.41% | ||
| OM | 15.78% | ||
| PM (TTM) | N/A | ||
| GM | 26.57% | ||
| FCFM | 5.9% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
ROICexc(3y)5.23%
ROICexc(5y)4.72%
ROICexgc(3y)18.5%
ROICexgc(5y)17.9%
ROCE(3y)6.37%
ROCE(5y)5.69%
ROICexgc growth 3Y0.78%
ROICexgc growth 5Y0.88%
ROICexc growth 3Y4.99%
ROICexc growth 5Y3.37%
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
F-Score4
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2 | ||
| Debt/FCF | 18.37 | ||
| Debt/EBITDA | 5.17 | ||
| Cap/Depr | 58.56% | ||
| Cap/Sales | 2.67% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 42.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.72 | ||
| Altman-Z | 0.76 |
F-Score4
WACC9.02%
ROIC/WACC0.62
Cap/Depr(3y)68.21%
Cap/Depr(5y)61.64%
Cap/Sales(3y)3.1%
Cap/Sales(5y)2.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
EPS Next Y-29.92%
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
EPS Next 5Y12.89%
Revenue 1Y (TTM)10.14%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%
Revenue Next Year6.88%
Revenue Next 2Y7.52%
Revenue Next 3Y7.62%
Revenue Next 5Y7.88%
EBIT growth 1Y15.88%
EBIT growth 3Y15.97%
EBIT growth 5Y12.77%
EBIT Next Year41.53%
EBIT Next 3Y20.05%
EBIT Next 5YN/A
FCF growth 1Y32.24%
FCF growth 3Y92.28%
FCF growth 5Y30.27%
OCF growth 1Y18.25%
OCF growth 3Y51.04%
OCF growth 5Y18.3%
SURGERY PARTNERS INC / SGRY FAQ
Can you provide the ChartMill fundamental rating for SURGERY PARTNERS INC?
ChartMill assigns a fundamental rating of 3 / 10 to SGRY.
What is the valuation status for SGRY stock?
ChartMill assigns a valuation rating of 4 / 10 to SURGERY PARTNERS INC (SGRY). This can be considered as Fairly Valued.
How profitable is SURGERY PARTNERS INC (SGRY) stock?
SURGERY PARTNERS INC (SGRY) has a profitability rating of 4 / 10.
What is the financial health of SURGERY PARTNERS INC (SGRY) stock?
The financial health rating of SURGERY PARTNERS INC (SGRY) is 2 / 10.
What is the earnings growth outlook for SURGERY PARTNERS INC?
The Earnings per Share (EPS) of SURGERY PARTNERS INC (SGRY) is expected to decline by -29.92% in the next year.